lymphoma large cell diffuselymphoma B cellchilddoi:10.1002/(SICI)1097-0142(20000515)88:10<2378::AID-CNCR24>3.0.CO;2Mark A. Lones M.DMitchell S. Cairo M.DSherrie L. Perkins M.D., Ph.DCancerMaunsell E, Allard P, Dorval M, Labbe J: A brief pain diary for ambulatory patie...
The redirection of T cells has emerged as an attractive therapeutic principle in B cell non-Hodgkin lymphoma (B-NHL). However, a detailed characterization of lymphoma-infiltrating T cells across B-NHL entities is missing. Here we present an in-depth T cell reference map of nodal B-NHL, base...
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured wi
38 The LBCL cases also included 3 T-cell rich B-cell lymphomas (TCRBCL; 2 were focally CD30+); 2 CD30+ primary mediastinal LBCLs; 1 follicular large cell lymphoma with CD30+ tumor cells and 1 LP HD with a syncytial large cell lymphoma component (Table 1). Immunohistochemical ...
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
If T cell markers are negative, then it is “null phenotype.”EMA+ indicates poor prognosis.Cytotoxic (granzyme B, TIA-1, perforin) molecules+ Classical/common; lymphohistiocytic; small (ALK nuclear; small cells CD30−); Hodgkin-like pattern; composite pattern; sarcomatoid; giant cell rich;...
CD8+ tumor-infiltrating T lymphocytes (T-TILs) in the tumor microenvironment (TME) play an important role in tumor development, and miRNAs regulate tumor cell interactions with the microenvironment. T-TIL-based tumor immunotherapy provides a promising tr
prognosis [140]. Kroemer et al. discovered that after surgery for CRLM, the expansion of CD4+T cells is associated with poor prognosis [141]. This aligns with the findings of Katz et al., who observed a negative correlation between CD4+T-cell content and post-CRLM surgery survival. The ...
Cutaneous T cell lymphoma (CTCL) represents a heterogeneous group of non-Hodgkin lymphoma distinguished by the presence of clonal malignant T cells. The heterogeneity of malignant T cells and the complex tumor microenvironment remain poorly characterized